Search DIAN Tissue Requests
Henrietta Nielsen
Apolipoprotein E isoform levels and their relevance to the development of AD pathology
03/11/2020
not approved
DIAN-T2003
By use of mass-spectrometry assess and compare the individual apolipoprotein E isoform levels in plasma and CSF from familial AD patients versus controls
To investigate whether fluid levels of apolipoprotein E are related to the estimated year of disease onset, CSF and imaging AD biomarkers in familial AD patients
To elucidate a potential correlation between plasma apolipoprotein E levels and previously assessed CSF alpha-synuclein levels whereof the latter appeared related to amyloid-beta deposition and symptom onset
Jérôme Braudeau
Optimization of a blood diagnosis of the silent phase of Alzheimer's disease
03/11/2020
not approved
DIAN-T2004
Confirm the performance of a diagnostic algorithm developed on European plasma samples.
Improve the algorithm by learning on human plasma samples of more varied genetic origin and environmental background.
Improve the algorithm by learning on human plasma samples collected longer before the diagnosis of Alzheimer's disease.
1) Dr. Alison M. Goate, 2) Dr. Sarah M. Neuner
Defining the role of microglia in Alzheimer’s disease risk and resilience
04/01/2020
approved
DIAN-T2005
Aim 1: Investigate the effect of high-risk or protective amyloid precursor protein (APP) mutations on microglia cell function.
Randall Bateman
Identification and validation of novel AD biomarkers for clinical development of Eisai AD pipelines
07/02/2020
withdrawn
DIAN-T2006
To profile of CSF MTBR-tau isoforms which can be captured by E2814 across all DIAD stages using CSF samples from DIAN-observation cohort.
Laura Ibanez
Plasma cell-free RNA as non-invasive biomarker for neurodegeneration
08/05/2020
not approved
DIAN-T2007
Validate genomic models for disease pathology in Autosomal Dominant Alzheimer
Develop a specific predictive model for ADAD
Ronald Hawley
TEST BIO SUBMISSION
08/07/2020
test the form
test the form 2
test the form 3
test the form 4
Teunissen
Add-on DIAN project 3 Novel mechanisms: pilot OLINK proteomics in left-over CSF aliquots
08/14/2020
not approved
DIAN-T2009
Study which OLINK proteins (signature) are discriminative between ADAD and controls
Compare with sporadi AD
Compare with Mass Spec in ADAD
Charlotte Teunissen
Measurement of glial fibrillary acidic protein (GFAP) levels in blood for evaluation of astrocyte reaction in Alzheimer disease.
08/14/2020
approved
DIAN-T2010
Determine trajectory of GFAP over the ADAD disease course in relation to amyloid
Oscar Harari
Metabolomic and lipidomics changes in ADAD
08/13/2020
approved
DIAN-T2011
Determine metabolite signatures of ADAD
Identify locus-metabolite and lipids associations via Metabolite genome-wide association studies (M-GWAS).
Rawan Tarawneh
VE-cadherin in Alzheimer Disease
04/04/2021
not approved
DIAN-T2103
Examine the diagnostic value of CSF and plasma levels of VE-cadherin as a marker of vascular injury in EOAD
Investigate whether VE-cadherin correlates with CSF and imaging measures of amyloid, tau, brain atrophy, and glucose hypometabolism in EOAD in cross-sectional and longitudinal analyses
Determine whether baseline VE-cadherin levels influences age of onset or rate of cognitive decline in asymptomatic and symptomatic mutation carriers